Freenome

Freenome

Freenome is a cancer screening company founded by Gabriel Otte.

No article has been written about this topic yet.
Paste a URL about this topic to auto-extract knowledge.
Visit our Writing Guide for help on how to write about a topic,
and check out an example of a well filled out topic page.

No article has been written about this topic yet.
Be the first one to add some text.

Loading AI-assisted edit mode...

Timeline

May 26, 2020

Freenome announces initiation of the PREEMPT CRC Clinical Trial, a registrational study for the early detection and prevention of colorectal cancer using a multiomics blood test.

July 2019

Freenome raises a $160,000,000 series B round from T. Rowe Price, Kaiser Permanente Ventures, Andreessen Horowitz, Polaris Partners, Roche Venture Fund, RA Capital Management, Perceptive Advisors and Verily Life Sciences.

March 2017

Freenome raises a $65,000,000 series A round from Asset Management Ventures, GV, Data Collective, Innovation Endeavors, s28 Capital, Andreessen Horowitz, Polaris Partners, Charles River Ventures and Founders Fund.

Funding rounds

Funding round
Funding type
Funding round amount (USD)
Funding round date
Investment
3 Results
Page 1 of 1
Results per page:
Powered by Golden Research Engine

People

Name
Role
LinkedIn

Christina Zeidan

Employee

Gabriel Otte

Founder

Michael Otte

Founder

Further reading

Title
Author
Link
Type
Date

Documentaries, videos and podcasts

Title
Date
Link

Companies

Company
CEO
Location
Products/Services

News

Title
Author
Date
Publisher
Description
BioSpace
May 26, 2020
BioSpace
Freenome , a privately held biotechnology company that has pioneered a comprehensive multiomics platform for early cancer detection with a routine blood draw, announced several new developments: initiating its PREEMPT CRC clinical trial; adding Gary Reedy, CEO of the American
Jonathan Shieber
July 24, 2019
TechCrunch
One of the major problems that technology companies working to find a cure for cancer need to solve is finding a safe, minimally invasive way to detect cancers early. Almost all cancer screening will eventually require a biopsy, but determining whether that's necessary in the early stages of cancer can mean the difference between life [...]

References

Golden logo
Text is available under the Creative Commons Attribution-ShareAlike 4.0; additional terms apply. By using this site, you agree to our Terms & Conditions.